Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis

Atherosclerosis. 2013 Apr;227(2):429-36. doi: 10.1016/j.atherosclerosis.2013.01.022. Epub 2013 Jan 29.

Abstract

Objective: While nonalcoholic fatty liver disease (NAFLD) is associated with the metabolic syndrome, it is not known if NAFLD plays an independent role in the atherogenic dyslipidemia phenotype.

Methods and results: The Multi-Ethnic Study of Atherosclerosis (MESA) is a population-based prospective cohort study of adults free of clinical cardiovascular disease at enrollment. We tested for a relationship between NAFLD, defined as a liver/spleen (L/S) attenuation ratio of <1 on a non-contrast cardiac CT scan, and multiple measures of fasting serum lipoprotein size, cholesterol and particle concentrations. NAFLD was present in 569 (17%) of 3362 participants. After adjustment for multiple metabolic risk factors, adiposity and measures of insulin resistance (HOMA-IR), NAFLD was independently associated with higher fasting serum triglycerides and lower serum HDL-C. Despite a lack of association with LDL-C, NAFLD was associated with higher LDL particle concentration and lower LDL particle size. Modeling the L/S ratio as a continuous variable, a severity dependent association was observed between atherogenic lipoprotein abnormalities and NAFLD.

Conclusion: In a large, multi-ethnic, gender balanced cohort, CT-diagnosed NAFLD was associated with the atherogenic dyslipidemia phenotype in a dose dependent fashion. These relationships persisted after adjustment for several metabolic risk factors and HOMA-IR, suggesting a possible independent pathophysiologic role between NAFLD and dyslipidemia.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Aged, 80 and over
  • Atherosclerosis / blood*
  • Atherosclerosis / ethnology*
  • Blood Glucose / metabolism
  • Cross-Sectional Studies
  • Dose-Response Relationship, Drug
  • Ethnicity
  • Fatty Liver / blood*
  • Fatty Liver / ethnology*
  • Female
  • Humans
  • Lipoproteins / blood*
  • Liver / pathology
  • Male
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease
  • Phenotype
  • Prevalence
  • Prospective Studies
  • Risk Factors
  • Spleen / pathology

Substances

  • Blood Glucose
  • Lipoproteins